On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Foundation Medicine (United States)

InstitutionResearch output, impact & collaborations

Foundation Medicine (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Foundation Medicine (United States)?

ScholarIQrecord summary

Foundation Medicine (United States) is a research organisation in Cambridge. OpenAlex records 2,342 works and 564,571 citations for it. 597 researchers list it as their most recent affiliation.

How many works does Foundation Medicine (United States) have?

ScholarIQindexed works

Foundation Medicine (United States) has 2,342 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Foundation Medicine (United States) have?

ScholarIQcitation count

Foundation Medicine (United States) has 564,571 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Foundation Medicine (United States)?

ScholarIQresearcher count

Foundation Medicine (United States) has 597 researchers in the ScholarIQ index.

What is the average h-index at Foundation Medicine (United States)?

ScholarIQavg h-index

Foundation Medicine (United States) has an average h-index of 51 in OpenAlex.

What is the ROR of Foundation Medicine (United States)?

ScholarIQror

The ROR for Foundation Medicine (United States) is on the source record.

What is the OpenAlex record for Foundation Medicine (United States)?

ScholarIQopenalex

The OpenAlex for Foundation Medicine (United States) is on the source record.

Who are the most-cited researchers behind Foundation Medicine (United States)?

ScholarIQtop researchers by citations
1
Priti S. Hegde · Cancer Immunotherapy and Biomarkers
264 works34,019 citations

What are the most-cited papers on Foundation Medicine (United States)?

ScholarIQmost cited works
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
Nature Medicine. 20181,263 CitationsOPEN ACCESS
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde
Proceedings of the National Academy of Sciences. 2018240 CitationsOPEN ACCESS

How much of the research on Foundation Medicine (United States) is open access?

ScholarIQopen access share
100%OPEN ACCESS
Gold
0%
Green
50%
Hybrid
0%
Bronze
50%
Closed
0%

Related on ScholarIQ

470M+ articles · 14-day free trial